NASDAQ:GRAY - Graybug Vision Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.50
  • Forecasted Upside: 42.55 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$23.50
▼ -1.87 (-7.37%)
1 month | 3 months | 12 months
Get New Graybug Vision Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRAY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$33.50
▲ +42.55% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Graybug Vision in the last 3 months. The average price target is $33.50, with a high forecast of $41.00 and a low forecast of $27.00. The average price target represents a 42.55% upside from the last price of $23.50.
Buy
The current consensus among 6 polled investment analysts is to buy stock in Graybug Vision.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/20/2020OppenheimerInitiated CoverageOutperform$41.00Low
i
10/20/2020Robert W. BairdInitiated CoverageOverweight$27.00High
i
10/20/2020SVB LeerinkInitiated CoverageOutperform$35.00High
i
Rating by M. Goodman at SVB Leerink LLC
10/20/2020WedbushInitiated CoverageOutperform$41.00High
i
Rating by L. Moussatos at Wedbush
10/20/2020Piper SandlerInitiated CoverageOverweight$27.00High
i
10/20/2020Needham & Company LLCInitiated CoverageBuy$30.00High
i
(Data available from 11/29/2015 forward)
Graybug Vision logo
Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.
Read More

Today's Range

Now: $23.50
$23.02
$25.93

50 Day Range

MA: $19.29
$13.16
$33.93

52 Week Range

Now: $23.50
$12.50
$37.88

Volume

71,713 shs

Average Volume

135,862 shs

Market Capitalization

$493.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A